 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- IL-12 engineered TIL / National Cancer Institute
Trial primary completion date, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - May 12, 2014
P1/2, N=34, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> Dec 2017
- IL-12 engineered TIL / National Cancer Institute
Trial completion date, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - May 12, 2014
P1/2, N=34, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> Dec 2017 Trial completion date: Oct 2014 --> Dec 2017
- IL-12 engineered TIL / National Cancer Institute
Trial suspension, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - Aug 7, 2013
P1/2, N=31, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2014 --> Dec 2017 Recruiting --> Suspended
- IL-12 engineered TIL / National Cancer Institute
Enrollment change, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - Aug 7, 2013
P1/2, N=31, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=103 --> 31